Equillium (EQ) Income from Continuing Operations (2018 - 2026)
Equillium (EQ) posted quarterly Income from Continuing Operations of 15947000.0 for Q1 2026, down 81.36% year-over-year from 85553368.52 in Q1 2025, and down 298.58% quarter-over-quarter from 4001000.0 in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Income from Continuing Operations for 9 consecutive years, with 15947000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 81.36% year-over-year to 15947000.0; the TTM figure through Mar 2026 stood at 34778000.0 (down 145.52% YoY), while the FY2025 annual figure was 22398000.0, down 176.31% from the prior year.
- Income from Continuing Operations retreated to 15947000.0 in Q1 2026 per EQ's latest filing, from 4001000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 17908000.0 in Q4 2022 and bottomed at 37417000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6678058.82 across 5 years, with a median of 4001000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 272.09% — and 2025, when it plunged 124528.57%.
- Equillium's Income from Continuing Operations stood at 17908000.0 in 2022, then plunged by 119.9% to 3564000.0 in 2023, then sank by 63.66% to 5833000.0 in 2024, then surged by 31.41% to 4001000.0 in 2025, then slumped by 298.58% to 15947000.0 in 2026.
- Business Quant data shows EQ's Income from Continuing Operations at 15947000.0 in Q1 2026, 4001000.0 in Q4 2025, and 8724000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -4.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.65 Mn |
| Mar 31, 2026 | -5.30 Mn |
| Dec 31, 2025 | -3.66 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.70 Mn |
| Dec 31, 2024 | -3.82 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 953,000.00 |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.98 Mn |
| Dec 31, 2022 | 15.88 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.76 Mn |
| Sep 30, 2021 | -10.12 Mn |